ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia
- 1 February 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 103 (2), 317-326
- https://doi.org/10.1097/01.aog.0000110246.93627.17
Abstract
The objective of this study was to assess the safety and efficacy of a novel therapeutic, ZYC101a, for the treatment of women with histologically confirmed cervical intraepithelial neoplasia (CIN) 2/3. ZYC101a contains plasmid-DNA-encoding fragments derived from the E6 and E7 proteins of human papillomavirus (HPV) 16 and 18, and is formulated within small biodegradable microparticles. A multicenter, double-blind, randomized, placebo-controlled trial was conducted in a group of women with biopsy-confirmed CIN 2/3. Subjects were randomized to 3 intramuscular doses of either placebo or ZYC101a (100 or 200 microg). Six months after the first injection, subjects underwent cervical conization. The primary endpoint for this study was histologically confirmed resolution of CIN 2/3. A total of 161 subjects were randomized, dosed, and evaluated for safety. After central pathology review, 127 subjects were evaluable for efficacy. The most common adverse events were related to the injection site, were mild to moderate, and did not worsen at later treatments. The proportion of subjects who resolved was higher in the ZYC101a groups compared to placebo (43% versus 27%), but the difference was not statistically significant (P =.12). In a prospectively defined population of women younger than 25 years (n = 43), resolution was significantly higher in the combined ZYC101a groups compared to placebo (70% versus 23%; P =.007). ZYC101a activity was not restricted to HPV-16-or HPV-18-positive lesions. ZYC101a was shown to be well tolerated in all patients and to promote the resolution of CIN 2/3 in women younger than 25 years. IKeywords
This publication has 20 references indexed in Scilit:
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Risk factors for early cytologic abnormalities after loop electrosurgical excision procedureObstetrics & Gynecology, 2002
- Interobserver Reproducibility of Cervical Cytologic and Histologic InterpretationsRealistic Estimates From the ASCUS-LSIL Triage StudyJAMA, 2001
- Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CINGynecologic Oncology, 2000
- Effects of β-Carotene and Other Factors on Outcome of Cervical Dysplasia and Human Papillomavirus InfectionGynecologic Oncology, 1997
- Hybrid Capture™ Method for Detection of Human Papillomavirus DNA in Clinical Specimens: A Tool for Clinical Management of Equivocal Pap Smears and for Population ScreeningJournal of Obstetrics and Gynaecology Research, 1996
- A comparison of early (E7) and late (L1) primer-mediated amplification of papillomaviral DNA in cervical neoplasiaMolecular and Cellular Probes, 1996
- A Randomized Prospective Study Comparing Three Techniques of Conization: Cold Knife, Laser, and LEEPGynecologic Oncology, 1994
- Enhancement of Regression of Cervical Intraepithelial Neoplasia II (Moderate Dysplasia) With Topically Applied All- trans -Retinoic Acid: a Randomized TrialJNCI Journal of the National Cancer Institute, 1994
- Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatmentBJOG: An International Journal of Obstetrics and Gynaecology, 1992